Summit Therapeutics SMMT EV / sales
EV / sales at other companies
Other financials
Where this comes from
Calculated from Summit Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Summit Therapeutics’s 10-Q, filed August 6, 2024, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's ev / sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's EV / sales?
- Summit Therapeutics (SMMT) reported EV / sales of 8,448.1× in Q2 2023.
- How has Summit Therapeutics's EV / sales changed year-over-year?
- Summit Therapeutics's EV / sales increased by 2571.7% year-over-year, from 316.2× to 8,448.1×.
- What is the long-term trend for Summit Therapeutics's EV / sales?
- Over 2 years (2020 to 2022), Summit Therapeutics's EV / sales has grown at a 13.6% compound annual growth rate (CAGR), from 3,759.7× to 4,851.5×.
- What does EV / sales mean?
- What the whole business costs relative to its annual sales.
- How do you interpret EV / sales?
- A fallback valuation gauge for pre-profit or cyclical firms. Like P/S, only comparable across similar-margin businesses, but it accounts for debt and cash unlike P/S.
- How does EV / sales compare across companies?
- Compare within a margin cohort; the debt-and-cash adjustment makes it cleaner than P/S for leveraged firms.